Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/13875
DETERMINATION OF ZALCITABINE IN MEDICAMENTS BY DIFFERENTIAL PULSE VOLTAMMETRY
Afiliação
Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Departamento de Química. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sérgio Arouca. Rio de Janeiro, RJ, Brasil.
Pontifícia Universidade Católica do Rio de Janeiro. Departamento de Química. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sérgio Arouca. Rio de Janeiro, RJ, Brasil.
Pontifícia Universidade Católica do Rio de Janeiro. Departamento de Química. Rio de Janeiro, RJ, Brasil
Resumo em Inglês
The zalcitabine (ddC) has been extensively used in the treatment of HIV patients due to its antiretroviral activity. The quality control
of this active principle in medications is of outstanding importance to public health. The principal objective of the current study
was the development of an alternative analytical methodology for the zalcitabine determination using a voltammetric process. The zalcitabine gives a reduction peak (at−1.22V versus Ag/AgCl) at the hanging mercury drop electrode (HMDE). The differential pulse voltammetric response is evaluated with respect to the scan rate (20 mV/s), pulse amplitude (50 mV), support electrolyte (Clark-Lubs buffer), pH (2.0), and other variables. The response is linear over the 10.0 to 28.0 mg/L (47 to 133𝜇M) concentration
range, and the detection limit is 2.08 mg/L. The validation of thismethod was realized using a governmental Brazilian document (Inmetro, 2007) and the results are reported for medication drugs.
Compartilhar